Cellectis S.A.
CLLSNASDAQHealthcare● Active
$3.03
+$0.10(+3.43%)
Market Cap$304314058
P/E Ratio—
52W High$5.48
52W Low$1.327
Cellectis S.A. (CLLS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLLS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($67.80M) | ($36.70M) | ($116.83M) | ($98.69M) | ($96.75M) |
| Depreciation & Amort. | $20.12M | $19.84M | $18.52M | $18.43M | $14.16M |
| Stock-Based Comp. | $0.00M | $0.00M | $5.23M | $6.04M | $11.49M |
| Change in Working Capital | ($41.72M) | $53.57M | ($3.99M) | ($5.72M) | ($12.30M) |
| Net Cash from Operations | ($40.14M) | $22.10M | ($24.75M) | ($87.44M) | ($104.56M) |
| Investing Activities | |||||
| Capital Expenditure | ($2.37M) | ($2.58M) | ($1.07M) | ($2.44M) | ($18.56M) |
| Purchases of Investments | ($160.27M) | ($162.48M) | $0.00M | $0.00M | ($0.14M) |
| Sales of Investments | $134.24M | $63.69M | $0.00M | $0.13M | $15.00M |
| Net Cash from Investing | ($29.58M) | ($102.63M) | ($15.51M) | ($2.76M) | $7.28M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | ($0.57M) | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($5.40M) | $18.17M | $24.56M | ($6.60M) | ($10.64M) |
| Net Cash from Financing | ($16.20M) | $89.80M | $82.86M | $1.15M | $47.52M |
| Free Cash Flow | |||||
| Free Cash Flow | ($42.50M) | $19.52M | ($25.82M) | ($89.89M) | ($123.12M) |
| FCF Margin %(computed) | -58.27% | 47.04% | — | -468.86% | -405.71% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Cellectis S.A. data
About Cellectis S.A. (CLLS) Cash Flow Statement
Cellectis S.A. generated operating cash flow of ($0.04B) and free cash flow of ($0.04B) for 2025 — a FCF margin of -58.27%. Capital expenditure was ($0.00B).
Frequently asked questions
CLLS · 4 questionsCellectis S.A. generated free cash flow of ($0.04B) for 2025, down 317.7% year-over-year.
CLLS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10